MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.44
+0.40
+3.62%
After Hours: 11.44 0 0.00% 16:00 09/18 EDT
OPEN
10.99
PREV CLOSE
11.04
HIGH
11.58
LOW
10.99
VOLUME
64.12K
TURNOVER
--
52 WEEK HIGH
18.45
52 WEEK LOW
7.00
MARKET CAP
400.34M
P/E (TTM)
-11.8072
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average XENE stock price target is 23.67 with a high estimate of 25.00 and a low estimate of 22.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XENE
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.